All In Biotech

Drug Trial Radar · NCT07735104

The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLS2319 for Injection/Placebo Following Single-Dose Administration in Healthy Subjects and Multiple-Dose Administration in Subjects With Cancer Cachexia.

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Oct 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia

Conditions

  • Cancer Cachexia
  • Cancer Cachexia Syndrome

Interventions

  • QLS2319Drug

    QLS2319 will be administered via subcutaneous injection

  • PlaceboDrug

    placebo will be administered via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia:Safety and tolerability after a single subcutaneous injection of QLS2319/placeboTime frame: Up to Day 99
  2. Phase Ib:Safety and tolerability after multiple subcutaneous injections of QLS2319Time frame: Up to 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Sun-Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.